CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER for: 020702, S018

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW

1. Organization CDER/HFD-510
Division of Metabolism and Endocrine Drug Products

2. NDA # 20-702
Approved: 17-DEC-1996

3. Name And Address Of Applicant
Parke-Davis Pharmaceutical Research
Division of Warner-Lambert Company
2800 Plymouth Road
P.O. Box 1047
Ann Arbor, MI 48106-1047 (313) 966-5000

4. Supplement SEI-018
Doc.03-MAR-1999 Rec.04-MAR-1999

5. Name of the Drug
Lipitor Tablets

6. Nonproprietary Name
Atorvastatin Calcium

7. Supplement provides support for the use of Lipitor (Atorvastatin Calcium) tablets to decrease the non HDL-C/HDL-C ratio and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial) and mixed dislipidemia (Fredrickson Type IIa and Type IIb)

8. Amendment –

9. Pharmacological Category Lipid Modifier. HMG-CoA reductase inhibitor/ Antihyperlipoproteinemic agent.

10. How Dispensed

11. Related
-N. A.-

12. Dosage Form Tablet

13. Potency 10-, 20- And 40-mg

14. Chemical Name And Structure

Atorvastatin Calcium

$(C_{33}H_{34}FN_2O_5)_2Ca$



CAS 134523-03-8
CAS 134523-00-5 (atorvastatin)
FW 2 x 557.7 + 40.0 = 1155.38
FW calcium salt trihydrate $(C_{33}H_{34}FN_2O_5)_2Ca.3H_2O$ = 1209.42
FW free acid $C_{33}H_{35}FN_2O_5$ = 558.66

1*H*-Pyrrole-1-heptanoic acid, 2-(4-flourophenyl)-β,–δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-,calcium salt (2:1), [*R*-(*R**,*R**)]-

15. Comments: This **Efficacy Supplement** provides the information to support for the use of Lipitor (Atorvastatin Calcium) 10-, 20- and 40-mg tablets to decrease the non HDL-C/HDL-C ratio and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial) and mixed dislipidemia (Fredrickson Type IIa and Type IIb). Approved drug substance, Atorvastatin Calcium, and drug product, Lipitor 10-, 20- and 40-mg. Tablets will be used for this indications. No Environmental Assessment is required.

16. Conclusions And Recommendations Since there are no changes in chemistry, manufacture and controls of both drug substance and drug product, this **supplement is approvable from the chemistry view point.**

17. Reviewer Name (and signature) /S/ Xavier Ysern, PhD

Date Completed 18-OCT-1999

R/D Init.

filename: /nda/20702s18.doc

DISTRIBUTION: Original: NDA 20-702 cc: HFD-510 Division File/ SMoore/ MSimoneau / XYsern

AE /S/ 10/18/99